News Detail
London, 10 May 2018: Scientists at the Institute of Cancer Research (ICR) in the U.K. have harnessed CRISPR-Cas9 genome-editing technology to uncover why some tumors are resistant to poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib and ta......
View Details
Source : Genetic Engineering & Biotechnology News
Related News
- New target to beat cancer drug resistance (21-09-2023)
- New implantable device carries insulin-producing islet cells to control diabetes (20-09-2023)
- IIT Madras Researchers Developing A Portable, Turnkey Device To Detect Heavy Metals In Soil & Water (20-09-2023)
- Understanding Medicinal Drug Delivery Using Dry Powder Inhalers (DPIs) (20-09-2023)
- Molnupiravir: Concerns raised about possibility of creating new, treatment-resistant versions of the virus (19-09-2023)
- Various PFAS associated with breast, ovary, skin and uterus cancers in women (19-09-2023)
- IIT Jodhpur researchers develop antimicrobial peptide from snake venom (18-09-2023)
- Metformin, a common diabetes drug, can prevent muscle atrophy and fibrosis (17-09-2023)
- Layered Black Phosphorus Nanoflakes can kill antibiotic resistant superbugs (16-09-2023)
- Implantable bioartificial kidney aims to free patients from dialysis (14-09-2023)